E2 ModerateHigher confidencePEM requiredLongitudinalPeer-reviewedReviewed
Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A Report from the Observational RECOVER-Adult Study.
Vernon, Suzanne D, Zheng, Tianyu, Do, Hyungrok et al. · Journal of general internal medicine · 2025 · DOI
Quick Summary
This study tracked over 11,000 people who had COVID-19 and about 1,400 who didn't, following them for at least 6 months to see how many developed ME/CFS. Researchers found that people who had COVID-19 were nearly 5 times more likely to develop ME/CFS compared to people who never had COVID-19. About 4.5% of COVID-infected participants developed ME/CFS, compared to only 0.6% of uninfected people.
Why It Matters
This is the first large-scale study to quantify how often ME/CFS develops specifically after COVID-19, providing critical epidemiological data that validates ME/CFS as a documented post-infection complication. These findings support the need for ME/CFS recognition, screening protocols, and clinical management guidelines in post-COVID care, while also advancing understanding of infection-triggered ME/CFS mechanisms.
Observed Findings
- ME/CFS incidence was 2.66 per 100 person-years in SARS-CoV-2 infected participants compared to 0.93 in uninfected controls (hazard ratio 4.93).
- 4.5% of COVID-infected participants (531/11,785) met ME/CFS diagnostic criteria versus 0.6% of uninfected participants (9/1,439).
- Post-exertional malaise was the most common ME/CFS symptom, occurring in 24.0% (2,830/11,785) of infected participants.
- 88.7% of participants with post-COVID-19 ME/CFS (471/531) also met RECOVER criteria for long COVID.
Inferred Conclusions
- SARS-CoV-2 infection significantly increases the risk of developing ME/CFS, with infected individuals nearly 5 times more likely to develop the condition than uninfected controls.
- ME/CFS is a diagnosable and measurable sequela of COVID-19, distinct from but frequently overlapping with broader long COVID presentations.
- Post-exertional malaise represents a key clinical feature of post-COVID-19 ME/CFS and should be a focus of clinical screening and management.
Remaining Questions
- What underlying biological mechanisms (viral persistence, immune dysfunction, mitochondrial dysfunction, etc.) drive the development of post-COVID-19 ME/CFS?
- Why do some infected individuals develop ME/CFS while others don't, and are there identifiable risk factors (genetic, immunological, viral variants) that predict susceptibility?
What This Study Does Not Prove
This study does not establish what biological mechanisms cause post-COVID-19 ME/CFS, nor does it determine whether all cases are identical or involve different pathways. The reliance on self-reported symptoms means some mild cases may go undetected while borderline cases could be misclassified, and symptom fluctuation over time could affect prevalence estimates.
Tags
Method Flag:PEM_DEFINEDStrong PhenotypingSex-Stratified
Symptom:Post-Exertional MalaiseFatigue
Phenotype:Infection-TriggeredLong COVID Overlap
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.